Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A.

Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/S0140-6736(10)60893-8. Epub 2010 Jul 6.

PMID:
20609468
2.

[Olaparib in ovarian cancer with BRCA mutation].

Pujade-Lauraine É, Combe P.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S82-4. doi: 10.1016/S0007-4551(15)31221-2. Review. French.

PMID:
26118881
3.

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.

Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Liu Q, Venugopal R, Ibrahim A, Pazdur R.

Clin Cancer Res. 2015 Oct 1;21(19):4257-61. doi: 10.1158/1078-0432.CCR-15-0887. Epub 2015 Jul 17. Review.

4.

Olaparib: a promising PARP inhibitor in ovarian cancer therapy.

Chen Y, Zhang L, Hao Q.

Arch Gynecol Obstet. 2013 Aug;288(2):367-74. doi: 10.1007/s00404-013-2856-2. Epub 2013 Apr 26. Review.

PMID:
23619942
5.

Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.

Munroe M, Kolesar J.

Am J Health Syst Pharm. 2016 Jul 15;73(14):1037-41. doi: 10.2146/ajhp150550. Review.

PMID:
27385701
6.

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.

Nirsimloo R, Gourley C.

Expert Rev Anticancer Ther. 2016 Jun;16(6):597-603. doi: 10.1080/14737140.2016.1182429. Review.

PMID:
27115428
7.

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.

Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.

Expert Opin Investig Drugs. 2016;25(5):597-611. doi: 10.1517/13543784.2016.1156857. Epub 2016 Mar 16. Review.

PMID:
26899229
8.

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.

Tewari KS, Eskander RN, Monk BJ.

Clin Cancer Res. 2015 Sep 1;21(17):3829-35. doi: 10.1158/1078-0432.CCR-15-0088. Epub 2015 Jul 13. Review.

9.

[Hereditary ovarian carcinomas: clinico-biological features and treatment].

Floquet A, Stoeckle E, Croce S, Longy M, Mc Grogan G, Barouk E, Bubien V, Garbay D, Joly E, Guyon F.

Bull Cancer. 2014 Feb;101(2):167-74. doi: 10.1684/bdc.2014.1888. Review. French.

PMID:
24555961
10.

Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.

Frampton JE.

BioDrugs. 2015 Apr;29(2):143-50. doi: 10.1007/s40259-015-0125-6. Review.

PMID:
25899311
11.

Safety evaluation of olaparib for treating ovarian cancer.

Lheureux S, Bowering V, Karakasis K, Oza AM.

Expert Opin Drug Saf. 2015 Aug;14(8):1305-16. doi: 10.1517/14740338.2015.1045875. Epub 2015 Jun 8. Review.

PMID:
26051946
12.

Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.

Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J.

Cochrane Database Syst Rev. 2015 May 20;(5):CD007929. doi: 10.1002/14651858.CD007929.pub3. Review.

PMID:
25991068
13.

Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.

Parkes EE, Kennedy RD.

Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28. Review.

14.

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.

Gunderson CC, Moore KN.

Future Oncol. 2015;11(5):747-57. doi: 10.2217/fon.14.313. Review.

PMID:
25757679
15.

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].

Schreiber V, Illuzzi G, Héberlé E, Dantzer F.

Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15. Review. French.

PMID:
26384693
17.

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.

Miller RE, Ledermann JA.

Clin Adv Hematol Oncol. 2016 Aug;14(8):619-27. Review.

PMID:
27487106
18.

Advances in PARP inhibitors for the treatment of breast cancer.

Dizdar O, Arslan C, Altundag K.

Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20. Review.

PMID:
26485111
19.

Olaparib (Lynparza) for advanced ovarian cancer.

[No authors listed]

Med Lett Drugs Ther. 2016 Feb 29;58(1489):e32-3. Review. No abstract available.

PMID:
26938702
20.

Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.

Friedlander M, Banerjee S, Mileshkin L, Scott C, Shannon C, Goh J.

Asia Pac J Clin Oncol. 2016 Dec;12(4):323-331. doi: 10.1111/ajco.12636. Review. Erratum in: Asia Pac J Clin Oncol. 2017 Aug;13(4):337.

PMID:
27917619

Supplemental Content

Support Center